Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M.
Soverini S, et al. Among authors: martinelli g.
J Clin Oncol. 2006 Nov 20;24(33):e51-2. doi: 10.1200/JCO.2006.08.9128.
J Clin Oncol. 2006.
PMID: 17114651
No abstract available.